At the forefront of research, development, commercialization of innovative, and potential     best-in-class total solutions for valvular heart diseases



CardioFlow Announces 2021 Interim Results

Shanghai, China — MicroPort CardioFlow Medtech Corporation, announced on August 29, 2021 the interim results of the company for the six months ended June 30, 2021. During the period, the company recorded revenue of RMB86.2 million, representing an increase of 121.8% as compared to the corresponding period of last year, with the gross profit margin increased significantly by 11 percentage points to 55.1%.


The announcement of annual results of MicroPort CardioFlow Medtech Corporation for the year 2020

MicroPort CardioFlow Medtech is pleased to announce the results of the Company and its subsidiaries for the year ended December 31st, 2020


MicroPort CardioFlow Completes Raising New Round of Funds

MicroPort CardioFlow had completed raising a new round of funds on the basis of a pre-money valuation of US$1.1 billion. The introduction prominent strategic investors, who are CPE, Hillhouse Capital Management, Ltd., Lake Bleu Capital, Gamnat, China Reform Conson Soochow Overseas Fund I L.P., Gortune Artemis Limited, and 3H Health Investment Fund I, L.P., raised approximately US$130 million.


First “post-marketing” implantation in Western China for the TAVI procedure with VitaFlow® was performed by Professor Tao Lin on September 23, 2019

First “post-marketing” implantation in Western China for the TAVI procedure with VitaFlow® was performed at the Department of Cardiology of Xijing Hospital, the surgery was led by cardiology experts Professor Tao Lin and Professor Lifei.


First “post-marketing” implantation of the VitaFlow® Valve System was successfully performed at Guangdong General Hospital

On September 19, 2019, the first “post-marketing” implantation of the VitaFlow® Valve System and Alwide® Balloon in Lingnan Region was successfully performed by the team of Prof. Luo Jianfang at Guangdong General Hospital.


First “post-marketing” implantation for the procedure performed by Professor Ge on August 28, 2019

Shanghai, China - on August 28, 2019, the first implantation of the self-developed VitaFlow® Transcatheter Aortic Valve System of MicroPort Cardioflow was performed at Zhongshan Hospital affiliated to Fudan University. Prof. Ge Junbo, Academician of Chinese Academy of Sciences, Director of the Cardiology Department of Zhongshan Hospital, performed the surgery and successfully implanted the VitaFlow® aortic valve into a 70-year-old male patient.